GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

First author	Publication year	Country	Population	Age (control vs. intervention)	Sample size (control vs. intervention)	Type of study	Type of intervention	Control group	Duration
Fan et al.	2013	China	NAFLD + T2DM + obesity	54.68 ± 12.14; 51.02 ± 10.10	68/49	RCT	Exenatide	Metformin	12 weeks
Shao et al.	2014	China	NAFLD + T2DM	42 ± 3.2; 43 ± 4.1	30/30	RCT	Exenatide + insulin glargine	Insulin aspart + insulin glargine	12 weeks
Armstrong et al.	2016	UK	NASH with/without T2DM	18–70	7/7	Double-blind, randomized, placebo-controlled trial	Liraglutide	Placebo	12 weeks
Armstrong et al.	2016	UK	NASH with/without T2DM	50 ± 12; 50 ± 11	22/23	Multicentre, double-blinded, randomized, placebo-controlled phase 2 trial	Liraglutide	Placebo	48 weeks
Khoo et al.	2017	Singapore	NAFLD + obesity	43.7 ± 10.4; 39.0 ± 8.1	12/12	Pilot randomized trial	Liraglutide	Diet + exercise	26 weeks
Wang et al.	2017	China	NAFLD + T2DM	40–78; 41–75	49/49	RCT	Exenatide + metformin	Metformin	12 weeks
Feng et al.	2017	China	NAFLD + T2DM	48.07 ± 12.59; 46.79 ± 9.68	29/14.5	Single-center, open-label, prospective, and randomized trial with parallel design	Liraglutide	Gliclazide	24 weeks
Feng et al.	2017	China	NAFLD + T2DM	46.31 ± 12.32; 46.79 ± 9.68	29/14.5	Single-center, open-label, prospective, and randomized trial with parallel design	Liraglutide	Metformin	24 weeks
Tian et al.	2018	China	NAFLD + T2DM	56.4 ± 8.4; 58.5 ± 7.6	75/52	RCT	Liraglutide	Metformin	12 weeks
Yan et al.	2019	China	NAFLD + T2DM	45.7 ± 9.2; 43.1 ± 9.7	27/12	Randomized, open-label, active-controlled, parallel-group, multicenter trial	Liraglutide	Sitagliptin	26 weeks
Yan et al.	2019	China	NAFLD + T2DM	45.6 ± 7.6; 43.1 ± 9.7	24/12	Randomized, open-label, active-controlled, parallel-group, multicenter trial	Liraglutide	Insulin glargine + metformin	26 weeks
Khoo et al.	2019	Singapore	NAFLD	43.6 ± 9.9; 38.6 ± 8.2	15/15	Prospective randomized pilot study	Liraglutide	Diet + exercise	26 weeks